Oxymetazoline - RDD Pharma

Drug Profile

Oxymetazoline - RDD Pharma

Alternative Names: RDD 0315

Latest Information Update: 24 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RDD Pharma
  • Class Decongestants; Eye disorder therapies; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Faecal incontinence
  • New Molecular Entity No

Highest Development Phases

  • Phase II Faecal incontinence

Most Recent Events

  • 17 Jul 2018 US FDA approves IND application for oxymetazoline in Faecal incontinence
  • 17 Jul 2018 RDD Pharma plans a phase I trial for Faecal incontinence in USA in the third quarter of 2018
  • 30 May 2018 RDD Pharma files an IND application with the US FDA in USA for Faecal incontinence
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top